Tandem Diabetes Care to Announce First Quarter 2019 Financial Results on April 30, 2019

SAN DIEGO–(BUSINESS WIRE)–Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery
and diabetes technology company, plans to release its first quarter 2019
results after the financial markets close on Tuesday, April 30, 2019.
The Company will hold a conference call and simultaneous webcast on the
same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its
first quarter 2019 financial and operating results.

Conference Call/Webcast Details:
Date:
April 30, 2019
Time: 4:30pm Eastern Time (1:30pm Pacific
Time)
Toll Free Dial-In Number: (855) 427-4396
International
Dial-In Number:
(484) 756-4261
Conference ID: 7583979
Webcast
Link:
https://edge.media-server.com/m6/p/28iv3jex

An archive of the webcast will be available for 30 days following the
event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com
in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach to
the design, development and commercialization of products for people
with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™
Insulin Pump, is capable of remote software updates using a personal
computer and features integrated continuous glucose monitoring. Tandem
is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslimX2 and
$TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow
Tandem Diabetes Care on LinkedIn at www.linkedin.com/company/TandemDiabetes.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a
trademark of Tandem Diabetes Care, Inc.

Contacts

Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com